Key Points
- Insider sale: Milos Miljkovic sold 3,573 shares at $6.82 on Jan. 6 for $24,367.86, cutting his stake by 5.73% to 58,820 shares; the transaction was disclosed in an SEC filing.
- Cartesian shares opened at $8.09 (up 4.3%), trading within a 12‑month range of $5.98–$20.12, with a market cap of $210.48M and a negative P/E of -5.19.
- The company reported an EPS miss of ($1.38) versus ($0.81) expected but beat revenue ($0.45M vs. $0.18M), and analysts maintain a consensus Moderate Buy with an average price target of $38 while institutions own about 86.95% of the stock.
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) insider Milos Miljkovic sold 3,573 shares of the firm's stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $6.82, for a total value of $24,367.86. Following the completion of the transaction, the insider directly owned 58,820 shares in the company, valued at approximately $401,152.40. This represents a 5.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Cartesian Therapeutics Stock Up 4.3%
Shares of Cartesian Therapeutics stock opened at $8.09 on Friday. The business has a 50-day moving average price of $7.38 and a 200-day moving average price of $9.58. Cartesian Therapeutics, Inc. has a twelve month low of $5.98 and a twelve month high of $20.12. The firm has a market cap of $210.48 million, a price-to-earnings ratio of -5.19 and a beta of 0.38.
Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.57). The business had revenue of $0.45 million during the quarter, compared to the consensus estimate of $0.18 million. On average, equities analysts expect that Cartesian Therapeutics, Inc. will post 4.56 EPS for the current fiscal year.
Hedge Funds Weigh In On Cartesian Therapeutics
A number of large investors have recently made changes to their positions in RNAC. AlphaQuest LLC grew its holdings in shares of Cartesian Therapeutics by 64.6% during the third quarter. AlphaQuest LLC now owns 6,924 shares of the company's stock worth $71,000 after purchasing an additional 2,717 shares in the last quarter. Virtus Investment Advisers LLC raised its holdings in Cartesian Therapeutics by 12.5% in the second quarter. Virtus Investment Advisers LLC now owns 9,183 shares of the company's stock worth $95,000 after purchasing an additional 1,023 shares in the last quarter. Miller Financial Services LLC bought a new stake in shares of Cartesian Therapeutics in the 2nd quarter worth approximately $121,000. Bank of America Corp DE grew its position in Cartesian Therapeutics by 133.0% during the 2nd quarter. Bank of America Corp DE now owns 13,933 shares of the company's stock valued at $145,000 after purchasing an additional 7,952 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in Cartesian Therapeutics by 27.5% during the 1st quarter. Rhumbline Advisers now owns 13,006 shares of the company's stock valued at $171,000 after purchasing an additional 2,805 shares during the last quarter. 86.95% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on RNAC shares. Wall Street Zen cut Cartesian Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, November 8th. HC Wainwright decreased their price target on shares of Cartesian Therapeutics from $40.00 to $30.00 and set a "buy" rating for the company in a research report on Wednesday, November 19th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Cartesian Therapeutics in a research note on Monday, December 29th. Finally, BTIG Research increased their price objective on Cartesian Therapeutics from $42.00 to $44.00 and gave the stock a "buy" rating in a report on Friday, November 14th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Cartesian Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $38.00.
Get Our Latest Report on RNAC
About Cartesian Therapeutics
(
Get Free Report)
Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian's technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.
At the core of Cartesian's approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
